Tower Research Capital LLC TRC Has $360,000 Stake in Masimo Co. (MASI)
Tower Research Capital LLC TRC grew its stake in Masimo Co. (NASDAQ:MASI) by 119.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,683 shares of the medical equipment provider’s stock after acquiring an additional 2,005 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Masimo were worth $360,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the company. Mount Yale Investment Advisors LLC purchased a new position in Masimo during the 1st quarter worth $101,000. Northwestern Mutual Wealth Management Co. purchased a new position in Masimo during the 2nd quarter worth $109,000. Cerebellum GP LLC purchased a new position in Masimo during the 2nd quarter worth $173,000. US Bancorp DE grew its stake in Masimo by 36.9% during the 2nd quarter. US Bancorp DE now owns 1,980 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 534 shares during the last quarter. Finally, Matisse Capital purchased a new position in Masimo during the 2nd quarter worth $202,000. Institutional investors and hedge funds own 83.25% of the company’s stock.
Shares of MASI stock opened at $123.25 on Friday. Masimo Co. has a 1-year low of $80.69 and a 1-year high of $124.65. The firm has a market cap of $6.42 billion, a P/E ratio of 50.59, a price-to-earnings-growth ratio of 2.90 and a beta of 1.02.
Several research analysts recently weighed in on the company. Stifel Nicolaus boosted their target price on Masimo from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Needham & Company LLC assumed coverage on Masimo in a research note on Friday, September 14th. They set a “buy” rating on the stock. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 17th. ValuEngine downgraded Masimo from a “buy” rating to a “hold” rating in a research note on Thursday, June 7th. Finally, Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $110.00 target price on the stock in a research note on Tuesday, July 3rd. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $102.60.
In other Masimo news, CEO Joe E. Kiani sold 60,074 shares of the business’s stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $109.05, for a total transaction of $6,551,069.70. Following the sale, the chief executive officer now owns 168,514 shares in the company, valued at approximately $18,376,451.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Steven Barker sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $110.00, for a total value of $1,100,000.00. Following the sale, the director now owns 74,832 shares in the company, valued at approximately $8,231,520. The disclosure for this sale can be found here. In the last quarter, insiders have sold 764,055 shares of company stock worth $90,505,831. Company insiders own 12.60% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: Google Finance
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.